Back to results
US 7,842,705 B2Granted
Curcumin analogs with anti-tumor and anti-angiogenic properties
AssigneeEmory University
InventorsJames P. Snyder, Matthew C. Davis, Brian Adams, Mamoru Shoji, Dennis C. Liotta, Eva M. Ferstl, Ustun B. Sunay
Life of this patent
Estimating the term…
Abstract
The present invention is directed to curcumin analogs exhibiting anti-tumor and anti-angiogenic properties, pharmaceutical formulations including such compounds and methods of using such compounds.
Claims30
A pharmaceutical formulation comprising a compound of the formula:
- wherein:
- the dashed lines indicate the presence of optional double bonds;
- X is O, S, or NR5,
- R1 and R2 are independently selected from the group consisting of halogen, hydroxyl, alkoxy, CF3, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;
- R3 and R4 are independently selected from the group consisting of H, halogen, hydroxyl, alkoxy, CF3, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;
- R5 is selected from the group consisting of H, alkyl, substituted alkyl, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl;
- or
- a pharmaceutically acceptable salt thereof;
- and
- a pharmaceutically acceptable carrier.
7 more elements
A method of treating cancerous tissue in a subject, comprising administering to the subject an effective amount of a compound of the formula
- wherein:
- the dashed lines indicate the presence of optional double bonds;
- X is O, S, or NR5,
- R1 and R2 are independently selected from the group consisting of halogen, hydroxyl, alkoxy, CF3, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;
- R3 and R4 are independently selected from the group consisting of H, halogen, hydroxyl, alkoxy, CF3, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;
- and
- R5 is selected from the group consisting of H, alkyl, substituted alkyl, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl;
- or
- a pharmaceutically acceptable salt thereof;
- wherein said cancerous tissue is selected from the group consisting of breast cancer, colon cancer, prostate cancer, skin cancer, leukemia, non-small cell lung cancer, CNS cancer, ovarian cancer, and renal cancer.
7 more elements
A method of treating an inflammatory skin condition in a subject, comprising administering to the subject an effective amount of a compound of the formula
- wherein:
- the dashed lines indicate the presence of optional double bonds;
- X is O, S, or NR5,
- R1 and R2 are independently selected from the group consisting of halogen, hydroxyl, alkoxy, CF3, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;
- R3 and R4 are independently selected from the group consisting of H, halogen, hydroxyl, alkoxy, CF3, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;
- and
- R5 is selected from the group consisting of H, alkyl, substituted alkyl, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl;
- or
- a pharmaceutically acceptable salt thereof.
6 more elements
Dependencies are inferred from the claim text.